Overview
BRTX market data
Price History
BRTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.58 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.82 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3,089.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.16 – $1.89 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $5.6M · P/B 29.24 · P/S 15.68.
Company News
Biorestorative Therapies Suspends All Orders, Shipments Of ExoCR, BioX Biocosmeceutical Product Lines Effective Immediately, On Aug 7; Conducting Review Of The Documentation, Sourcing, Regulatory Status Associated With Suspended Products; Has Not Made Decision To Discontinue Suspended Product LinesBenzinga · Aug 14, 2026, 8:48 PM
8-K filing — BioRestorative Therapies, Inc. (BRTX)SEC EDGAR · Aug 14, 2026, 8:15 PM
12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · Aug 7, 2026, 9:05 PM
BioRestorative Therapies Says Lance Alstodt Resigns As President, CEO, Chairman And All Other Positions Effective July 13, 2026; Robert Kristal Resigns As CFO And All Other Positions; Katharyn Field Appointed As CEO, President, And Interim CFOBenzinga · Jul 16, 2026, 9:45 PM
BioRestorative Therapies Completes Production For Its BRTX-100 Phase 2 Clinical Study To Support Current Clinical Development To Treat Chronic Lumbar Disc DiseaseBenzinga · Jun 25, 2026, 12:20 PM
Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 ResultsBenzinga · May 27, 2026, 2:40 PM
Kaos Capital Acquires 4.9% Of Issued And Outstanding Common Stock Of BioRestorative Therapies; Terms UndisclosedBenzinga · May 27, 2026, 11:47 AM
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline DataGlobenewswire Inc · May 26, 2026, 3:15 PM
BioRestorative Therapies Doses Last Participant In Its Phase 2 Clinical Study Of BRTX-100 To Treat Chronic Lumbar Disc DiseaseBenzinga · May 26, 2026, 3:03 PM